Caregen , a bio-peptide specialist, announced on the 10th that it will participate with a single booth in the global bio industry exhibition 'BIO International Convention 2025 (BIO USA)' to be held in Boston, USA from June 16th.
At this event, Caregen will focus on introducing products based on its peptide platform technology. Products on display include commercialized Korglutide, MyoKi, and ProGsterol, which are recording stable demand in the global market. Based on this, the company plans to secure new indications and diversify the market.
In addition, the main new drug pipeline under development will also be disclosed. Representative examples include CG-P5, a treatment for wet macular degeneration, and CG-T1, a treatment for dry eye syndrome, both of which have secured significant results in terms of safety and efficacy in preclinical and clinical stages. CG-P5 is a non-invasive treatment in the form of eye drops, and CG-T1 is known to have the potential to be applied to a wide range of ophthalmic diseases through its unique mechanism.
The company plans to further strengthen its strategic cooperation system within the global bio market by participating in BIO USA 2025. The exhibition booth (No. 3343) is designed to allow intuitive confirmation of the mechanisms, application fields, and clinical data of major products, and visitors will also be provided with opportunities for in-depth consultations and business meetings.
A Caregen official said, “BIO USA is an important platform where we can share the trends of the global bio industry and discover practical cooperation opportunities with global companies,” adding, “We will continue to expand our competitiveness in the global market based on our differentiated peptide technology.”
- See more related articles
You must be logged in to post a comment.